Idorsia Ltd
SIX:IDIA
Idorsia Ltd
Total Equity
Idorsia Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Idorsia Ltd
SIX:IDIA
|
Total Equity
-CHf1.1B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Total Equity
-$185.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Equity
$1.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
49%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Equity
CHf127.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
24%
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Total Equity
CHf76.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Total Equity
CHf32.6m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
Idorsia Ltd
Glance View
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
See Also
What is Idorsia Ltd's Total Equity?
Total Equity
-1.1B
CHF
Based on the financial report for Sep 30, 2025, Idorsia Ltd's Total Equity amounts to -1.1B CHF.
What is Idorsia Ltd's Total Equity growth rate?
Total Equity CAGR 3Y
-28%
Over the last year, the Total Equity growth was -1%. The average annual Total Equity growth rates for Idorsia Ltd have been -28% over the past three years .
